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Pnhibition of ErbB2 Causes
itochondrial Dysfunction in Cardiomyocytes
mplications for Herceptin-Induced Cardiomyopathy
uanda P. Grazette, MD, MPH,*† Wolfgang Boecker, MD,* Takashi Matsui, MD, PHD,*†
arc Semigran, MD,† Thomas L. Force, MD,‡ Roger J. Hajjar, MD,*† Anthony Rosenzweig, MD*†
oston, Massachusetts
OBJECTIVES We investigated the effects of erbB2 inhibition by anti-erbB2 antibody on cardiomyocyte
survival and mitochondrial function.
BACKGROUND ErbB2 is an important signal integrator for the epidermal growth factor family of receptor
tyrosine kinases. Herceptin, an inhibitory antibody to the erbB2 receptor, is a potent
chemotherapeutic but causes cardiac toxicity.
METHODS Primary cultures of neonatal rat ventricular myocytes were exposed to anti-erbB2 antibody
(Ab) (7.5 g/ml) for up to 24 h. Cell viability, mitochondrial function, and apoptosis were
measured using multiple complementary techniques.
RESULTS ErbB2 inhibition was associated with a dramatic increase in expression of the pro-apoptotic
Bcl-2 family protein Bcl-xS and decreased levels of anti-apoptotic Bcl-xL. There was a
time-dependent increase in mitochondrial translocation and oligomerization of bcl-associated
protein (BAX), as indicated by 1,6-bismaleimidohexane crosslinking. The BAX oligomer-
ization was associated with cytochrome c release and caspase activation. These alterations
induced mitochondrial dysfunction, a loss of mitochondrial membrane potential () (76.9 
2.4 vs. 51.7  0.1; p  0.05; n  4), a 35% decline in adenosine triphosphate levels (p 
0.05), and a loss of redox capacity (0.72  0.04 vs. 0.64  0.02; p 0.01). Restoration of
Bcl-xL levels through transactivating regulatory protein-mediated protein transduction
prevented the decline in  mitochondrial reductase activity and cytosolic adenosine triphos-
phate.
CONCLUSIONS Anti-erbB2 activates the mitochondrial apoptosis pathway through a previously undescribed
modulation of Bcl-xL and -xS, causing impairment of mitochondrial function and integrity
and disruption of cellular energetics. (J Am Coll Cardiol 2004;44:2231–8) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.066American College of Cardiology Foundation
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hrbB2 is a member of the epidermal growth factor (EGF)
amily of tyrosine (Tyr) kinase receptors and is overex-
ressed at high levels in a variety of cancers (1). A mono-
lonal antibody to erbB2, Trastuzumab (Herceptin, Genen-
ech Inc., San Francisco, California), has yielded significant
mprovements in response rate and survival in breast cancer
reatment (2). Early experience with the agent has also been
otable for cardiotoxicity and dramatic exacerbation of
nthracycline-induced cardiomyopathy, with up to a 27%
ncidence of moderate to severe cardiac dysfunction (2,3).
hereas the erbB receptors and their high-affinity ligands,
he neuregulins, have important roles in normal cardiac
evelopment (4), the basis of cardiac dysfunction after
nhibition of this system remains unclear.
Recently, two studies utilizing cardiac-specific deletion of
rbB2 demonstrated early cardiac dysfunction and severe
ilated cardiomyopathy in the absence of readily demon-
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004, accepted August 23, 2004.trable cardiomyocyte apoptosis (5,6). In both studies,
rbB2 conditional mutants were born with phenotypically
ormal hearts but developed dilated cardiomyopathy as
dults (5,6). Ozcelik et al. (6) saw no difference in apoptosis,
s measured by terminal deoxynucleotidyl transferase dUTP
ick end labeling (TUNEL) staining, between wild-type
nd conditional knockouts even after aortic banding. Their
nalysis suggested that erbB2 had a role in normal heart
hysiology but was not necessary for survival of cardiomy-
cytes (5,6). Crone et al. were also unable to detect any
ifference in TUNEL-positive cardiomyocytes but, using a
ighly sensitive polymerase chain reaction deoxyribonucleic
cid (DNA) fragmentation assay, were able to detect in-
reased DNA fragmentation in whole-ventricle samples
rom erbB2 conditional knockout mice (5). To test the
unctional significance of this potential low-level apoptosis,
he investigators overexpressed the anti-apoptotic Bcl-2
amily gene Bcl-xL. Expression of Bcl-xL resulted in partial
escue of chamber contractility and dilation (5). Whether
his functional rescue was due to inhibition of apoptosis or
ther effects of Bcl-xL is unknown.
Even though the Bcl proteins were first recognized for
heir role in apoptosis, they also modulate mitochondrial
omeostasis and integrity. In this study, we examined the
ffect of antibody-mediated erbB2 receptor antagonism on
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Anti-erbB2 Causes Mitochondrial Dysfunction December 7, 2004:2231–8itochondrial integrity and function, death pathway signal-
ng, and induction of apoptosis in rat cardiomyocytes. Here
e show that anti-erbB2 has significant adverse effects on
itochondrial function and energetics. Further, we demon-
trate that erbB2 inhibition is associated with a previously
ndescribed alteration in the expression and ratio of the
ntagonistic Bcl-2 family proteins Bcl-xL and -xS. This
hift in the apoptotic threshold leads to mitochondrial
ysfunction and caspase activation.
ATERIALS AND METHODS
ardiomyocyte isolation and experimental design. Neo-
atal rat ventricular cardiomyocytes (NRVM) were prepared
rom the hearts of Sprague-Dawley pups as previously
escribed (7). We tested multiple antibodies and selected
Ab clone 9G6 (Oncogene, Cambridge, Massachusetts) as
he inhibitory antibody used throughout these studies based
n its ability to bind the rat receptor (8) and to inhibit
eceptor kinase activity (9), as well as its ability to inhibit
eceptor phosphorylation in rat cardiomyocytes (data not
hown). Three days after plating cells in Dulbecco’s modi-
ed eagle medium with 5% fetal calf serum, 1% penicillin/
treptomycin were treated with anti-erbB2 Ab (clone 9G6)
r an isotype-matched control antibody (clone 122-25)
control Ab) (Oncogene, Cambridge, Massachusetts) at
oncentrations from 5 to 7.5 g/ml. To confirm the
unctional role of Bcl-xL, a cell-permeable peptide contain-
ng the N-terminal homology domain (BH4) linked to
arrier peptide human immunodeficiency virus (HIV)-TAT
TAT-BH4, Calbiochem, San Diego, California) (200 nM)
as added to NRVM 1 h before anti-erbB-2 Ab for selected
xperiments.
dult rat ventricular myocytes (ARVM) preparation. Adult
at ventricular myocytes were isolated and cultured from
earts excised from deeply anesthetized Sprague-Dawley
ats as has been previously described (10,11). Adult rat
entricular myocytes were treated immediately after plating
ith anti-erbB-2 Ab or the isotype control Ab at concen-
rations of 5 to 7.5 g/ml.
ibonucleic acid (RNA) interference. Neonatal rat ven-
ricular cardiomyocytes were transfected with a 21-base-pair
Abbreviations and Acronyms
ARVM  adult rat ventricular myocytes
ATP  adenosine triphosphate
DNA  deoxyribonucleic acid
EGF  epidermal growth factor
MTT  mitochondrial reductase activity
NRVM  neonatal rat ventricular cardiomyocytes
PBS  phosphate-buffered saline
RNA  ribonucleic acid
TUNEL  terminal deoxynucleotidyl transferase dUTP
nick end labeling
Tyr  tyrosineouble-stranded RNA duplex targeted to a sequence within ahe open reading frame of RNNEUR, the rodent erbB2
ene (AAGUGUGUACCGGCACAGACA) (Dharma-
on Research, Lafayette, Colorado). Sterile RNase-free
ater was added to the duplexed and desalted complex to
enerate 20-M duplex siRNA in annealing buffer. Each
0 mm plate was transfected with 30 l of 20-M, annealed
uplex. The duplex siRNA was added to Transit-TKO
ransfection reagent and serum-free Dulbecco’s modified
agle medium. After a 15-min incubation at room temper-
ture, the mixture was added to culture plates and incubated
or 24 h. Cells were analyzed for gene silencing at 48 and
2 h.
ell fractionation. Neonatal rat ventricular cardiomyo-
ytes were washed twice with cold phosphate-buffered saline
PBS), collected and resuspended in an isotonic buffer
ontaining Hepes pH 7.5, 20 mM, Sucrose 250 mM, NaCl
0mM, 1.5mM MgCl2, EGTA 1 mM, EDTA 1 mM with
rotease inhibitors. After 30 min on ice, cells were mechan-
cally disrupted and centrifuged (750 g for 10 min) to pellet
n-lysed cells and nuclei. Supernatants were collected and
entrifuged at 16,000 g for 20 min to pellet the
itochondria-rich heavy membrane fraction. The superna-
ant (cytosolic fraction) was removed and the heavy mem-
rane pellet was suspended in lysis buffer supplemented with
% triton. Protein concentrations of the fractions were
qualized, and sodium dodecyl sulfate sample buffer was
dded to a final concentration of 1X.
MH crosslinking. To detect BAX homo-oligomerization,
he irreversible cross-linker 1,6-bismaleimidohexane was ob-
ained from Pierce (Rockford, Illinois). A 10-mM stock
olution in dimethyl sulfoxide was added to mitochondrial
ractions at a 1:11. Crosslinking took place for 30 min at room
emperature, followed by centrifugation to pellet mitochondria.
mmunoblot analysis. Protein extraction and immuno-
lotting was performed as previously described (7). Cell
ysates were matched for protein concentration and were
hen separated by sodium dodecyl sulfate-polyacrylamide
el electrophoresis and transferred to Hybond-C extra
Amersham Pharmacia Biotech, Buckinghamshire, United
ingdom).
Primary antibodies were used to the following: BAD,
cl-xL, and BAX (Santa Cruz Biotechnology Inc.),
hospho-erbB2 (originally raised to human Tyr-877, which
orresponds to and cross-reacts with rat phospho-Tyr882,
s an indicator of receptor activation), erbB2 (9G6, as an
nhibitory antibody), caspase 9, cleaved caspase 9, caspase 3,
leaved caspase 3, phosphor-bcl-2 (Ser-70), phospho-bad
Ser-112, Ser-136) (New England Biolabs Inc.), cyto-
hrome c (Pharmingen, San Diego, California), and cyto-
hrome oxidase IV (Molecular Probes, Eugene, Oregon), all
t 1:1000.
ytochrome c quantitative sandwich enzyme immunoas-
ay. Neonatal rat ventricular cardiomyocytes were cultured
n 12-well plates at a density of 500,000/well. Twenty-four
ours after treatment, cells were collected and fractionated
s described and cytosolic cytochrome c was measured using
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December 7, 2004:2231–8 Anti-erbB2 Causes Mitochondrial Dysfunctionhe Quantikine M rat/mouse cytochrome c immunoassay
ccording to the manufacturer’s directions. Cytosolic frac-
ions were pipetted in triplicate onto a microplate precoated
ith rat/mouse cytochrome c. After a 2-h incubation and
ashing, substrate solution was added to each well. The
eaction was stopped after 30 min and the optical density
as measured at 540 using the Wallac Victor2 1420
ultilable Counter (Perkin Elmer, Boston, Massachusetts).
itochondrial reductase activity (MTT). Mitochondrial
eductase activity was measured in 96 well plates using the
ACS MTT Assay (R&D, Minneapolis, Minnesota)
ccording to the manufacturer’s protocol. Mitochondrial
eductase activity (3-[4, 5-dimethylthiazol-2-yl]-2,
-diphenyltetrazolium bromide), which is reduced to an
nsoluble formazan dye in metabolically active cells, was
dded 4 h before assay. Absorbance was measured at 595
sing the Biorad 3550 microplate reader.
iability/cytotoxicity. Neonatal rat ventricular cardiomyo-
ytes in 96-well flat bottom plates were cultured as de-
cribed. Quantification of live versus dead cells was achieved
imultaneously using calcein AM (Molecular Probes),
hich is well retained and fluoresces green (ex/em 495/515)
n living cells and ethidium homodimer (Molecular Probes),
hich enters damaged membranes and undergoes enhanced
ed fluorescence (ex/em 495/635) upon binding to nucleic
cids. Fluorescence was measured using the Wallac Victor2
420 Multilable Counter.
hange in mitochondrial membrane potential (). The
itochondrial selective dye MitoTracker Red (Molecular
robes) was used to label cells for flow cytometry. At 24 h
he MitoTracker probe was added to NRVM at 100-nM
nal concentration. Cells were incubated for 15 min at
7°C, washed with PBS, and fixed in 3% paraformaldehyde.
low cytometry was performed using a Becton Dickinson
ACSCAN. Data were collected by Cellquest software and
nalyzed with Cellfit software.
easurement of adenosine triphosphate (ATP) concen-
ration. Neonatal rat ventricular cardiomyocytes were cul-
ured in white 96-well flat-bottom plates at a density of
0,000/well. Adenosine triphosphate content was measured
sing the Apoglow (Cambrex, East Rutherford, New Jer-
ey) luciferin-luciferase bioluminescence kit following the
anufacturer’s protocol.
NA end labeling (TUNEL). For in situ detection of
poptosis in individual cells, TUNEL staining was per-
ormed using the MEBSTAIN Apoptosis Kit Direct ac-
ording to the manufacturer’s recommendations. Cardio-
yocytes were identified by simultaneous immunostaining
ith the anti–sarcomeric-actinin monoclonal Ab (EA-53,
igma, St. Louis, Missouri) labeled with Cy3 tagged goat
ntimouse immunoglobulin G secondary Ab (Sigma). For
uantification of the number of apoptotic cardiomyocytes,
uclei were counterstained with Hoechst 33258 (Sigma)
nd the total numbers of nuclei and TUNEL-positive nuclei
ere counted in actinin-positive cells in 8 to 10 low- tower fields in three independent experiments. More than
,500 nuclei were counted for each condition.
NA fragmentation (DNA laddering). The DNA lad-
ering was performed as previously described (7): 1 g
NA from each sample was labeled with 0.5 Ci [32P]
CTP (DuPont NEN, Boston, Massachusetts) in the
resence of 5 U of Klenow polymerase. The reaction was
erminated (10-mmol/l EDTA, 75°C for 10 min) and
ubjected to 1.8% agarose gel electrophoresis and
utoradiography.
ropidium iodide flow cytometry. Cells were fixed with
0% ethanol/PBS, washed with PBS, and resuspended in
BS with propidium iodide 20 g/ml and RNase type IIa
Sigma). Analyses were performed using a Becton Dickin-
on FACSCAN. Gating was performed to exclude small
ebris. The hypo-diploid population of cells was considered
poptotic. Data were analyzed by Cellfit software. Results
hown are from eight independent experiments.
tatistical analysis. Statistical analysis was carried out
sing the Prism software package (Graphpad, San Diego,
alifornia). Comparisons between groups were made using
nalysis of variance followed by Student-Newman-Keuls
ultiple-comparisons post-testing. Significance was ac-
epted at a value of p  0.05. Values are expressed as the
rithmetic mean  SEM.
ESULTS
nhibition of erbB2. We tested multiple antibodies to
dentify an appropriate inhibitory antibody for use with rat
ardiomyocytes. MAb clone 9G6 inhibits erbB2 tyrosine
inase activity in human cell lines (9) and cross-reacts with
he rat receptor homologue (8). Phosphorylation of the rat
rbB2 receptor at Tyr882 appears necessary for full receptor
ctivation and mitogenesis (12). Using a phosphospecific
ntibody corresponding to this site, we saw40% decline in
eceptor phosphorylation in cultured cardiomyocytes treated
ith mAb 9G6 compared with untreated or isotype-
atched control Ab-treated cells (data not shown). For
hese reasons, mAb 9G6 was used as the inhibitory anti-
rbB2 mAb throughout these studies.
lteration in Bcl-x expression. ErbB2 inhibition was
ssociated with a dramatic increase in expression of Bcl-xS,
hich was generally not detectable in cardiomyocytes at
aseline. In contrast, expression of Bcl-xL, which was
obust in untreated cardiomyocytes, decreased substantially
ver 24 h of anti-erbB2 treatment (Fig. 1A). To confirm
hat these effects were specifically due to erbB2 inhibition,
e also used RNA interference to reduce erbB2 receptor
xpression. Ribonucleic acid interference to erbB2 substan-
ially reduced erbB2 expression and mediated changes in
cl-xL and -xS expression similar to those seen with
ntibody treatment (Fig. 1B). Thus, loss of erbB2 function,
hether through antibody blockade or reduced expression,
ramatically perturbs the ratio of Bcl-xL to -xS in favor of
he latter.
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Anti-erbB2 Causes Mitochondrial Dysfunction December 7, 2004:2231–8ctivation of mitochondrial death signaling. We next
xamined whether the observed alterations in Bcl protein
xpression led to activation of mitochondrial apoptotic
ignaling, as has been previously reported in other cell types
13). Anti-erbB2 induced a time-dependent increase in the
rotein level of BAX (Fig. 2A). There was also increased
ligomerization of BAX within the mitochondria-rich
igure 1. Effects of erbB2 inhibition on Bcl-xL and -xS expression. (a)
rbB2 inhibition was associated with an increase in expression of Bcl-xS
nd decreased expression of Bcl-xL in a time-dependent manner. Western
lot shown is representative of five independent experiments. (b) A
1-base-pair double-stranded ribonucleic acid sequence corresponding to a
ection within the open reading frame of the rodent erbB2 gene (Gralb)
as solubilized in TransIT-TKO (Mirus Research Solutions, Houston,
exas) for transfection of cardiomyocytes. Reduced expression of erbB2
nd altered Bcl-x expression were seen 48 h after transfection. Western
lots representative of four independent experiments.
igure 2. Activation of mitochondrial death agonists. Neonatal rat ventri
pecified times. Lysates were collected and separated by electrophoresis un
odium dodecyl sulfate-polyacrylamide gel electrophoresis. (a) Time-depe
ubjected to subcellular fractionation to yield a mitochondria rich heavy me
rosslinker BMH. Immunoblot demonstrates crosslinked BAX multimers.
eginning at 8 hours after anti-erbB2 treatment. (Lower panel) Cytochro
nduced a time-dependent increase in cleavage and activation of caspase 9
bserved beginning as early as 8 h after treatment. (Bottom panel) Actin immun
re representative of three or more independent experiments.eavy membrane fraction (HM) (Fig. 2B). Homo-
ligomerization of BAX, as demonstrated by BMH
rosslinking, has been shown to precede release of cyto-
hrome c (14). We observed depletion of cytochrome c from
he mitochondrial fraction, in a time-dependent fashion,
eginning at 8 h after anti-erbB2 treatment (Fig. 2C,
pper). Cytochrome c reached detectable levels in the
ytosolic fraction at 24 h as measured by cytochrome c
LISA (control, 0.47 0.05 and control Ab, 0.6 0.11 vs.
nti-erbB2 1.3  0.09, n  3, p  0.05). Cleavage and
ctivation of caspase 9, an initiator caspase in the mitochon-
rial pathway, also increased in a time-dependent manner
eginning at 16 h (Fig. 2D, lower). Cleavage of caspase 3,
downstream target of caspase 9 and important effector
aspase, was also documented by Western blotting (Fig. 2E,
iddle) and by caspase 3 activity assay (6,794  390 vs.
,628  481, p  0.05)
There were no significant changes in expression or
ocalization observed for Bcl-2, phospho-Bcl-2, BAD, or
hospho-BAD (data not shown).
dult cardiomyocytes. We also examined whether the
ownstream signaling consequences of anti-erbB2 could be
xtended to adult rat cardiomyocytes. Anti-erbB2 treatment
esulted in a marked increase in expression of Bcl-xS and a
oderate increase in Bcl-xL, resulting in a net increase in
he Bcl-xS/Bcl-xL ratio and an increase in BAX (Fig. 3A).
s with neonatal cardiomyocytes, this elevated Bcl-xS/
cl-xL and elevation in BAX was associated with an
ncrease in cytosolic cytochrome c (Fig. 3B).
itochondrial membrane potential (). Because Bcl-xL
as been reported to have an important role in maintaining
oth mitochondrial membrane potential and adenosine
cardiomyocytes were exposed to anti-erbB2 antibody (erbB2 Ab) for the
enaturing conditions with protein detection by immunoblotting following
t increase in expression of bcl-associated protein. (b) Treated cells were
e fraction (HM). The HM was incubated for 30 min with the irreversible
pper panel) Depletion of cytochrome c from the mitochondrial fraction,
xidase used for control of mitochondrial protein loading. (d) Anti-erbB2
nning at 16 h. (e) Increase cleavage and activation of caspase 3 were alsocular
der d
nden
mbran
(c) (U
me o
begioblotting to control for cytosolic protein loading. All Western blots shown
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December 7, 2004:2231–8 Anti-erbB2 Causes Mitochondrial Dysfunctioniphosphate/ATP exchange, we investigated the effect of
nti-erbB2 on these parameters (15,16). We initially used
he mitochondrial potential sensor Mitotracker red to eval-
ate the mitochondrial membrane potential (). Using flow
ytometry, we observed a 25% (p  0.05) decrease in red
uorescence in anti-erbB2–treated cells compared with
ontrols (Fig. 4A).
ntracellular ATP. To investigate whether these alterations
n mitochondrial integrity were sufficient to interfere with
ellular energetics, we compared the intracellular ATP reserves
f anti-erbB2, control Ab, and control untreated cells. There
as a substantial decrease in ATP-generated luminescence in
nti-erbB2-treated cells compared with untreated cells (35%
eduction, 847 75 vs. 1,297 112 cps, p 0.01) or control
ntibody-treated cells (25% decrease, 847  75 vs. 1,131 
7.2 cps, p  0.05) (Fig. 4B).
rbB-2 inhibition induces a loss of redox capacity in
eonatal cardiomyocytes. Reduction of the tetrazolium
ompound MTT is dependent upon the presence of nico-
inamide adenine dinucleotide and nicotinamide adenine
inucleotide phosphate, as well as intact mitochondrial
lectron transport. In cardiomyocytes reduction of MTT
ccurs primarily at the mitochondria and therefore reflects
itochondrial function and metabolic activity of cardiomy-
cytes. We found that erbB2 inhibition reduced mitochon-
rial reductase activity in cells exposed to anti-erbB2 for
4 h by 20% compared with untreated and isotype-matched
ntibody-treated controls (0.804 vs. 1.0, p  0.05, normal-
zed data) (Fig. 4C). To examine whether these changes
ere due to a decline in cell number, we performed calcein
M/ethidium homodimer vital staining in parallel with
TT and saw no change across treatment groups.
igure 3. Anti-erbB2 effects in adult rat ventricular myocytes. Adult rat
entricular myocytes were exposed to anti-erbB2 antibody (Ab) for the
pecified times. Lysates were collected, separated by electrophoresis, and
mmunoblotted. (a) ErbB2 inhibition was associated with an increase in
xpression of Bcl-xS and Bcl-xL. (b) Cytochrome c release into the cytosol.
ax  bcl-associated protein.Similar to NRVM, there was an approximate 18% decline An redox activity as measured by MTT in anti-erbB-2
reated compared with untreated and control Ab-treated
igure 4. Anti-erbB2 reduces mitochondrial membrane potential adeno-
ine triphosphate (ATP) concentration and redox capacity in neonatal rat
entricular cardiomyocytes. Neonatal rat ventricular cardiomyocytes were
tained with a fluorescent probe selective for metabolically active mito-
hondria Mitotracker red. (a) Results of flow cytometry of cells stained
ith Mitotracker red dye. Anti-erbB2 treatment resulted in decreased red
uorescence (76.85  2.4 vs. 51.1  0.072, *p  0.05, n  4 independent
xperiments). (b) ATP content was measured using luciferin-luciferase
ioluminescence. There was a 35% decrease in ATP content of anti-erbB2-
reated cells at 36 h compared to untreated cells. Results, expressed as
elative light units, are from three independent experiments with six
eplicates/condition (1,297  112 vs. 847  75, *p  0.01). (c) Reduction
f the tetrazolium salt mitochondrial reductase activity (MTT) to a
orresponding formazan is an indicator of redox capacity. Redox capacity
as quantified using a spectrophotometer at a wavelength of 590. Reported
esults represent pooled data from nine independent experiments with
hree or more replicates, for each condition reported, in each experiment
1.0 vs. 0.804, *p  0.01: normalized data pooled from nine independent
xperiments, three replicates/condition). Ab  antibody; M1%  percent
ositive of gated cells.RVM (0.076  0.005 vs. 0.062  0.002, p  0.01).
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Anti-erbB2 Causes Mitochondrial Dysfunction December 7, 2004:2231–8H4-TAT prevents anti-erbB2-induced mitochondrial
ysfunction. Bcl-xL, a close homologue of Bcl-2, pro-
otes cell survival. Anti-apoptotic Bcl-2 family members
hare sequence homology at multiple regions of the four
cl-2 homology (BH) domains, however BH4 is the only
omain conserved among all of the anti-apoptotic Bcl-2
roteins. The BH4 domain has been demonstrated to be
ecessary for binding to BAX (17), and deletion of the BH4
omain abrogates the anti-apoptotic activity of both Bcl-2
nd -xL (13). It has been previously demonstrated that the
onserved N-terminal region (BH4 domain) is both neces-
ary and sufficient for prevention of apoptotic mitochondrial
hanges (13). To confirm the functional significance of
educed Bcl-xL expression in this setting, we used a cell-
ermeable peptide containing BH4 domain of Bcl-xL
inked to the protein transduction domain of HIV-1,
IV-TAT. The cell-permeable Bcl-xL peptide completely
revented the decline in mitochondrial membrane potential,
TT activity, and intracellular ATP (Fig. 5). Thus, the
bserved reduction in Bcl-xL relative to Bcl-xS plays a
ritical role in mediating mitochondrial dysfunction after
rbB2 inhibition.
rbB-2 inhibition and apoptosis. To determine whether
hese changes in mitochondrial function and Bcl protein
xpression and mitochondrial apoptotic signaling induced
ncreased apoptosis in NRVMs, we utilized propidium
odide flow cytometry, TUNEL staining, and DNA ladder-
ng in parallel. Surprisingly, despite upstream activation of
he mitochondrial death pathway, there was only a modest
ncrease in apoptosis as measured by TUNEL staining (6.5
0.7% vs. 3.1  0.4%, p  0.05) (Figs. 6A and 6C) and
ow cytometry of propidium iodide-labeled NRVM (8.3 
.9% vs. 4.5  0.6%, p  0.01) (Fig. 6B). There was no
iscernible increase in DNA laddering (Fig. 6C). Although
NA laddering is highly specific, it is relatively insensitive
o low-level apoptosis, and this likely accounts for the
bsence of DNA laddering in our samples (18).
ISCUSSION
he erbB2 receptor is recognized as an oncogene in an
ncreasing variety of cancers including gastric, endometrial,
nd lung. The expansion of erbB2 inhibition as an impor-
ant chemotherapeutic modality is certain. However, early
rial experience with a monoclonal antibody to erbB2,
rastuzumab (Herceptin), was notable for up to a 27%
ncidence of moderate to severe cardiac dysfunction (2,3).
hereas the most severe cardiomyopathy occurred when
rastuzumab was combined with doxorubicin, Trastuzumab
lso caused significant cardiotoxicity when used in combi-
ation with paclitaxel and as monotherapy (2,3). Although
9% of the patients who developed cardiomyopathy in the
rastuzumab trials experienced symptomatic improvement
ith conventional CHF therapy, the long-term conse-
uences of exposure are unknown (3). A more complete
nderstanding of erbB2 signaling in the heart therefore has sual relevance. First, as a potentially vital signaling mech-
nism controlling cardiomyocyte viability, and second as a
eans of identifying potential novel therapeutic targets that
ould be used to mitigate anti-erbB2-associated toxicity.
In this study, we provide a potential contributing mech-
nism for anti-erbB2-associated cardiac toxicity. Antibody-
ediated inhibition of erbB2 was associated with dramatic
lterations in the ratio of Bcl-xL/Bcl-xS, activation of BAX,
nd significant mitochondrial dysfunction. Human immu-
odeficiency virus TAT-mediated transduction of the con-
igure 5. Transduction of TAT-BH4. To assess the functional signifi-
ance of reduced Bcl-xL expression, cardiomyocytes were pretreated with a
ell permeable Bcl-xL peptide (TAT-BH4). TAT-BH4 completely pre-
ented the decline in (a) mitochondrial membrane potential (70  0.57 vs.
1.2  1.26, *p  0.01, n  4 independent experiments), (b) intracellular
denosine triphosphate (5867  166 vs. 4946  272 relative light units, *p
0.01, n  5 independent experiments), and (c) MTT activity (1.070 
.02 vs. 0.9744  0.03, *p  0.05, n  5 independent experiments).
bbreviations as in Figure 4.erved BH4 Bcl-xL domain prevented mitochondrial dys-
f
t
t
r
A
i
c
g
s
p
s
c
G
l
A
t
t
i
I
o
h
r
p
t
i
o
d
a
o
m
t
c
d
n
c
a
i
p
a
s
d
t
u
c
d
p
h
v
c
o
h
s
a
F
t
(
(
a
P
4
n
a
d
and autoradiography.
2237JACC Vol. 44, No. 11, 2004 Grazette et al.
December 7, 2004:2231–8 Anti-erbB2 Causes Mitochondrial Dysfunctionunction, thus demonstrating the functional importance of
his alteration.
Bcl-2 family proteins, first recognized as central integra-
ors of death signaling, also play a closely related role in the
egulation of mitochondrial stability and function (19).
ctivation of BAX and loss of mitochondrial membrane
ntegrity is associated with multiple major deleterious intra-
ellular consequences including loss of electron transport,
eneration of free radicals, release of pro-apoptotic proteins
uch as cytochrome c, and the uncoupling of oxidative
hosphorylation so that ATP is hydrolyzed rather than
ynthesized (20–22). A recent report also establishes a
entral role for BAX in intracellular calcium cycling (23).
iven the high energy requirements of cardiomyocytes, it is
ikely that mitochondrial dysfunction and a reduction in
TP stores ultimately result in compromised cardiac func-
ion. In fact, several studies have documented that agents
hat interfere with mitochondrial energetics have a negative
mpact on cardiac contractility in vitro and in vivo (24,25).
nhibition of oxidative phosphorylation, as occurs in anoxia
r ischemia, leads to impairment or cessation of normal
eart function in animal models (26). Further, in ischemia-
eperfusion there is growing evidence that mitochondrial
ermeability transition pore (MPTP) opening is critical to
he transition from reversible to irreversible reperfusion
njury (26). It has also been demonstrated that MPTP
pening is not irreversible and that the extent of mitochon-
rial re-closure correlates with functional recovery (26–28).
If opening of the MPTP also plays an important role in
nti-erbB2 mediated myocyte injury, inhibitors of pore
pening, such as Bcl-xL, should offer protection. In our
odel, transduction of the BH4 Bcl-xL domain prevented
he reduction in ATP and mitochondrial dysfunction asso-
iated with erbB2 inhibition. Thus, rescue of mitochondrial
ysfunction by Bcl-xL may provide an alternative mecha-
ism by which overexpression of Bcl-xL ameliorates the
ardiomyopathy seen in erbB2-targeted mice, even in the
bsence of considerable apoptosis (5,6,29). Therapeutic
nterventions that inhibit or reverse MPTP opening may
rove useful in providing protection from apoptotic stimuli
nd potentially reversing diminished myocellular function.
Early investigations of neuregulin erbB signaling demon-
trated that neuregulin inhibited apoptosis after serum
eprivation (30). After inhibition of erbB2, which is essen-
ial in neuregulin signaling, we observed activation of
pstream apoptotic signaling. We also observed a statisti-
ally significant increase in apoptosis, although the absolute
egree of apoptosis was less than is generally seen with other
athophysiologically relevant stimuli (7). Chronic apoptosis,
owever, even at low levels, can contribute to loss of
entricular function and therefore cannot be ruled out as a
ontributing mechanism to trastuzumab-induced cardiomy-
pathy using this in vitro model (31). The present study,
owever, suggests that consequences of incomplete progres-
ion to apoptosis, such as mitochondrial dysfunction, likelyigure 6. Apoptosis. (a) Anti-erbB2 increased apoptosis as measured by
erminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
6.5  0.7% vs. 3.1  0.4%, *p  0.05, n  5 independent experiments).
b) Propidium iodide flow cytometry. Control, anti-erbB2, and control
ntibody (control Ab)-treated cells were fixed in ethanol and stained with
I. Anti-erbB2 increased the percentage of apoptotic cells. (8.3  0.9% vs.
.5  0.6%, *p  0.01, n  8 independent experiments). (c) Deoxyribo-
ucleic acid (DNA) laddering. DNA was collected from untreated,
nti-erbB2, and doxorubicin (positive control)-treated cells, radiolabeled as
escribed in Methods, and subjected to 1.8% agarose gel electrophoresis lso play a role. Several studies have previously demon-
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ng (32) and failing myocardium (33,34). Although the
unctional relevance and underlying mechanism of this
interrupted apoptosis” remain unclear, it is reasonable to
ypothesize that such cardiomyocytes may be functionally
mpaired and more susceptible to additional apoptotic
timuli. This increased susceptibility could account for the
otentiation of cardiotoxicity observed with erbB2 inhibi-
ion in the clinical arena. Importantly, incomplete initiation
f apoptosis with diminished myocellular function might
ffer opportunities for reverse remodeling and therapeutic
ntervention. Recognition of mitochondrial dysfunction as a
otential contributor to the cardiac dysfunction observed
ith erbB2 inhibition, even in the absence of overt apopto-
is, may therefore broaden the therapeutic approaches being
onsidered in this setting.
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